

University of Dundee

Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction

Carrick, David; Haig, Caroline; Maznyczka, Annette M.; Carberry, Jaclyn; Mangion, Kenneth; Ahmed, Nadeem

Published in:
Hypertension (Dallas, Tex. : 1979)

DOI:
[10.1161/HYPERTENSIONAHA.117.10786](https://doi.org/10.1161/HYPERTENSIONAHA.117.10786)

Publication date:
2018

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Carrick, D., Haig, C., Maznyczka, A. M., Carberry, J., Mangion, K., Ahmed, N., Yue May, V. T., McEntegart, M., Petrie, M. C., Eteiba, H., Lindsay, M., Hood, S., Watkins, S., Davie, A., Mahrous, A., Mordi, I., Ford, I., Radjenovic, A., Welsh, P., ... Berry, C. (2018). Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction. *Hypertension (Dallas, Tex. : 1979)*, 72(3), 720-730. <https://doi.org/10.1161/HYPERTENSIONAHA.117.10786>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction

David Carrick,* Caroline Haig,* Annette M. Maznyczka, Jaclyn Carberry, Kenneth Mangion, Nadeem Ahmed, Vannesa Teng Yue May, Margaret McEntegart, Mark C. Petrie, Hany Eteiba, Mitchell Lindsay, Stuart Hood, Stuart Watkins, Andrew Davie, Ahmed Mahrous, Ify Mordi, Ian Ford, Aleksandra Radjenovic, Paul Welsh, Naveed Sattar, Kirsty Wetherall, Keith G. Oldroyd, Colin Berry

Abstract—The rationale for our study was to investigate the pathophysiology of microvascular injury in patients with acute ST-segment–elevation myocardial infarction in relation to a history of hypertension. We undertook a cohort study using invasive and noninvasive measures of microvascular injury, cardiac magnetic resonance imaging at 2 days and 6 months, and assessed health outcomes in the longer term. Three hundred twenty-four patients with acute myocardial infarction (mean age, 59 [12] years; blood pressure, 135 [25] / 79 [14] mmHg; 237 [73%] male, 105 [32%] with antecedent hypertension) were prospectively enrolled during emergency percutaneous coronary intervention. Compared with patients without antecedent hypertension, patients with hypertension were older (63 [12] years versus 57 [11] years; $P<0.001$) and a lower proportion were cigarette smokers (52 [50%] versus 144 [66%]; $P=0.007$). Coronary blood flow, microvascular resistance within the culprit artery, infarct pathologies, inflammation (C-reactive protein and interleukin-6) were not associated with hypertension. Compared with patients without antecedent hypertension, patients with hypertension had less improvement in left ventricular ejection fraction at 6 months from baseline (5.3 [8.2]% versus 7.4 [7.6%]; $P=0.040$). Antecedent hypertension was a multivariable associate of incident myocardial hemorrhage 2-day post-MI (1.81 [0.98–3.34]; $P=0.059$) and all-cause death or heart failure ($n=47$ events, $n=24$ with hypertension; 2.53 [1.28–4.98]; $P=0.007$) postdischarge (median follow-up 4 years). Severe progressive microvascular injury is implicated in the pathophysiology and prognosis of patients with a history of hypertension and acute myocardial infarction.

Clinical Trial Registration—URL: <http://www.clinicaltrials.gov>. Unique identifier: NCT02072850.

(*Hypertension*. 2018;72:720–730. DOI: 10.1161/HYPERTENSIONAHA.117.10786.) • [Online Data Supplement](#)

Key Words: atherosclerosis ■ hypertension ■ myocardial infarction ■ prognosis ■ reperfusion injury

Hypertension has a continuous, age-related risk of mortality from ischemic heart disease.¹ At least 30% of adults have a history of hypertension in developed countries,^{2,3} and hypertension is independently associated with adverse cardiac outcome after acute myocardial infarction (MI).^{4–11} However, the mechanisms for this association are unclear. Patients who present with acute ST-segment–elevation myocardial infarction (STEMI) and a history of hypertension are older and generally have a higher burden of risk factors,^{11,12} except for cigarette smoking which associates with male sex and younger age.^{11,12} The size of infarction is a key determinant of survival post-MI, but previous studies^{11,12} have not found any association

between hypertension status and infarct size. Therefore, the mechanisms underlying the association between hypertension status and health outcomes post-MI remain unclear.

Hypertension is a risk factor for coronary heart disease.¹³ The pathophysiology includes left ventricular hypertrophy,¹⁴ coronary endothelial dysfunction,¹⁵ accelerated coronary atherosclerosis,^{16,17} abnormal coronary artery remodeling,¹⁸ coronary microvascular dysfunction,¹⁹ and epicardial fat.²⁰ Accordingly, preexisting coronary heart disease may predispose patients with antecedent hypertension to enhanced myocardial reperfusion injury. Severe microvascular injury within the infarct zone manifests acutely as microvascular obstruction affecting about

Received December 24, 2017; first decision January 16, 2018; revision accepted June 12, 2018.

From the British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (D.C., A.M.M., J.C., K.M., N.A., V.T.Y.M., M.M., M.C.P., I.M., A.R., P.W., N.S., K.G.O., C.B.); West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, United Kingdom (D.C., A.M.M., J.C., K.M., N.A., V.T.Y.M., M.M., M.C.P., H.E., M.L., S.H., S.W., A.D., A.M., I.M., K.G.O., C.B.); and Robertson Centre for Biostatistics, University of Glasgow, United Kingdom (C.H., I.F., K.W.).

*These authors contributed equally to this work.

This article was sent to Suzanne Oparil, Consulting Editor, for review by expert referees, editorial decision, and final disposition.

The online-only Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.117.10786>.

Correspondence to Colin Berry, British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, 126 University Pl, University of Glasgow, Glasgow G12 8TA, Scotland, United Kingdom. Email colin.berry@glasgow.ac.uk

© 2018 The Authors. *Hypertension* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Hypertension is available at <https://www.ahajournals.org/journal/hyp>

DOI: 10.1161/HYPERTENSIONAHA.117.10786

half of all-comers with STEMI,^{21,22} and subsequently resolving in half of these patients by 10 days.²² In patients with persistent microvascular obstruction, progressive irreversible capillary degradation occurs leading to infarct zone hemorrhage, which is an independent predictor of death or heart failure in the longer term.^{21,22} To date, the associations between antecedent hypertension and microvascular injury post-MI are unclear.

We investigated the natural history of hypertension status, microvascular pathology, and prognosis in all-comers with acute STEMI. We measured microvascular function directly in the culprit coronary artery acutely using a sensor mounted on an intracoronary guidewire and noninvasively using the surface ECG. We subsequently used multiparametric cardiac magnetic resonance (CMR) to assess the evolution of infarct pathologies and left ventricular function and volumes at 2-day and 6-month post-MI.

We hypothesized that a history of hypertension would be associated with enhanced microvascular dysfunction within the culprit coronary artery acutely, and more abundant microvascular pathologies, including microvascular obstruction and myocardial hemorrhage, independent of the size of infarction, when assessed using CMR 2 days later. This hypothesis implicates microvascular damage within the infarct zone as an underpinning mechanism leading to less myocardial salvage, greater adverse left ventricular remodeling, and an increased risk of heart failure and death after an acute MI.

Methods

The data that support the findings of this study can be requested from the following URL: <http://www.CORportal.net>.

Study Population

We performed a prospective cohort study in a regional cardiac center between July 14, 2011, and November 22, 2012. Written informed consent was obtained from all of the participants.

A history of hypertension was prospectively recorded if patients were prescribed antihypertensive treatment or had successive blood pressure (BP) measurements that were $\geq 140/90$ mmHg on at least 2 different days during the index hospitalization.²³ Noninvasive BP was measured in recumbent patients using an oscillometric method using an arm cuff pressure-sensitive transducer (GE CRITIKON, GE Healthcare, Amersham, United Kingdom) and automated medical patient monitoring system (DINAMAP and CARESCAPE Monitor B850, GE Medical Systems Information Technologies). Patients were categorized as having hypertension or not.

Patients were eligible if they had an indication for primary percutaneous coronary intervention (PCI) or thrombolysis for acute STEMI.²⁴ Exclusion criteria included contraindications to CMR, for example, a pacemaker. The study was approved by the National Research Ethics Service (reference 10-S0703-28). Acute STEMI management followed contemporary guidelines²⁴ (Methods in the [online-only Data Supplement](#)). The ClinicalTrials.gov identifier is URL: <http://www.clinicaltrials.gov>. Unique identifier: NCT02072850.

Electrocardiogram

A 12-lead ECG was obtained before coronary reperfusion and 60 minutes afterward. The extent of ST-segment resolution on the ECG assessed 60 minutes after reperfusion compared with the baseline ECG before reperfusion²⁴ was expressed as complete ($\geq 70\%$), incomplete (30% to $<70\%$), or none ($\leq 30\%$).

Coronary Angiogram Acquisition and Analyses

Coronary angiograms were acquired during usual care with cardiac catheter laboratory X-ray (Innova, GE Healthcare) and information technology equipment (Centricity, GE Healthcare). The angiograms were analyzed by trained observers (J. Carberry, V.T. Yue May) who were blinded to all other clinical and CMR data. The Thrombolysis In Myocardial Infarction (TIMI) coronary flow grade²⁵ and frame count²⁶ were assessed at initial

angiography and at the end of the procedure. TIMI myocardial perfusion grade²⁷ was assessed at the end of the procedure (Methods in the [online-only Data Supplement](#)). The TIMI frame count and perfusion grade are angiographic measures of microvascular function.

Direct, Invasive Measurement of Microvascular Function in the Culprit Coronary Artery

A coronary pressure- and temperature-sensitive guidewire (St Jude Medical, St Paul, MN) was used to measure index of microvascular resistance (IMR) and coronary flow reserve (CFR) in the culprit coronary artery at the end of PCI.^{28–32} The guidewire was calibrated outside the body, equalized with aortic pressure at the ostium of the guide catheter and then advanced to the distal third of the culprit artery. This thermomodulation method is based on the following basic relationship: $\text{flow} = \text{volume} / \text{mean transit time}$. CFR is defined as the ratio of peak hyperemic to resting flow ($\text{CFR} = \text{flow at hyperemia} / \text{flow at rest}$). Flow is the ratio of the volume (V) divided by the mean transit time (Tmn). Thus, CFR can be expressed as follows: $\text{CFR} = (\text{V}/\text{Tmn}) \text{ at hyperemia} / (\text{V}/\text{Tmn}) \text{ at rest}$. Assuming the epicardial volume (V) remains unchanged, CFR can be calculated as follows: $\text{CFR} = \text{Tmn at rest} / \text{Tmn at hyperemia}$. CFR and IMR are distinct physiological parameters. CFR reflects epicardial and microcirculatory function, by contrast, IMR is a direct invasive measure of microvascular resistance. IMR is defined as the distal coronary pressure multiplied by the mean transit time of a 3 mL bolus of saline at room temperature during maximal coronary hyperemia, measured simultaneously (mmHgxs or units).^{28–32}

Hyperemia was induced by 140 $\mu\text{g}/\text{kg}$ per minute of intravenous adenosine preceded by a 2 mL intracoronary bolus of 200 μg of nitrate. The mean aortic and distal coronary pressures were recorded during maximal hyperemia. We have previously found IMR to be highly repeatable when assessed by duplicate measurements 5 minutes apart in 12 consecutive STEMI patients at the end of PCI.³⁰

Laboratory Analyses

Serial systemic blood samples were obtained immediately after reperfusion in the cardiac catheterization laboratory and subsequently on the first day (06:00–07:00 hours) during the initial inpatient stay in the Coronary Care Unit.

CRP (C-reactive protein) was measured in the hospital biochemistry laboratory using a particle-enhanced immunoturbidimetric assay method (Cobas C501, Roche), and the manufacturer's calibrators and quality control material, as a biochemical measure of inflammation. The high-sensitive assay CRP measuring range is 0.1 to 250 mg/L. The expected CRP values in a healthy adult are <5 mg/L, and the reference range in our hospital is 0 to 10 mg/L. IL (interleukin)-6 was measured using a high-sensitivity enzyme-linked immunosorbent assay (ELISA; R&D Systems, Oxon, United Kingdom).³³ The limit of detection is <0.1 pg/mL, and the intra-assay coefficient of variation was 9.1%. NT-proBNP (N-terminal Pro-B-type natriuretic peptide) was measured in a research laboratory using an electrochemiluminescence method (e411, Roche) and the manufacturers' calibrators and quality control material. The limit of detection for IL-6 and NT-proBNP are 6.5 pg/mL and 5 pg/mL, respectively. Long-term coefficient of variations of low and high controls are typically $<5\%$ and were all within the manufacturers' range.

CMR Imaging

We used CMR to provide reference data on left ventricular function, pathology, and surrogate outcomes (Figure 1). CMR was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-Tesla scanner with a 12-element phased array cardiac surface coil.³² The imaging protocol^{34,35} (Methods in the [online-only Data Supplement](#)) included cine CMR with steady-state free precession, T2-mapping,^{22,36,37} T2*-mapping,²² and delayed-enhancement phase-sensitive inversion-recovery pulse sequences.³⁸ The scan acquisitions were spatially coregistered and also included different slice orientations to enhance diagnostic confidence.

Imaging Analyses

The CMR analyses are described in detail in the [online-only Data Supplement](#). Left ventricular dimensions were indexed to body surface area.




Figure 1. Two patients, one with a history of hypertension (**A**) and the other without (**B**) presented similarly with acute anterior ST-segment-elevation myocardial infarction and were treated by primary percutaneous coronary intervention (PCI) with stents. The antithrombotic therapies, including aspirin, clopidogrel, and unfractionated heparin, were similar. Each patient had normal antegrade flow in the culprit coronary artery (Thrombolysis In Myocardial Infarction grade 3) at the end of PCI. Multiparametric cardiovascular magnetic resonance (CMR) imaging was performed 2 d and 6 mo later. **Top, A**, Imaging obtained from a 52-year-old man with a history of current hypertension. The symptom-to-balloon time was 1.4 h. The coronary angiogram revealed a proximal occlusion of the left anterior descending artery. Blood pressure before coronary angioplasty was 200/125 mmHg and measured 181/117 mmHg postcoronary angioplasty. Two days later, CMR disclosed myocardial hemorrhage specifically revealed by T2* mapping (yellow arrows) and transmural infarction of the anteroseptal wall of the left ventricle (LV; yellow arrows) associated with microvascular obstruction revealed by contrast CMR. Invasive assessment of microvascular function using a diagnostic guidewire placed in the culprit coronary artery at the end of primary PCI indicated severe microvascular injury. The index of microvascular resistance measured 92 which is substantially increased (reference range <25). The initial infarct size was 38.9%, and the LV ejection fraction (LVEF) and LV end-diastolic volume indexed to body surface area (LVEDVi) were 48.5% and 90.2 mL/m², respectively. Six months later, infarct size was 26.7% of LV mass, and the LVEDVi was 127 mL/m². This is in-keeping with >20% in LVEDVi, that is, adverse remodeling. This patient went to have an unplanned admission for heart failure treatment on day 493 of follow-up. **Bottom, B**, Imaging obtained from a 58-year-old man with no prior history of hypertension. The symptom-to-balloon time was 2.2 h. The angiogram also revealed a proximal occlusion of the left anterior descending artery. Blood pressure before coronary angioplasty was 109/71 mmHg and measured 99/60 mmHg postcoronary angioplasty. Microvascular resistance in the culprit coronary artery was normal. Two days later, there was a small amount of microvascular obstruction as revealed by contrast-enhanced CMR (yellow arrows), and no evidence of myocardial hemorrhage (T2 star parametric map). The initial infarct size was 32.4%, and the LVEF and LVEDVi were 36.9% and 126.4 mL/m², respectively. Six months later, infarct size was 15.2% of left ventricular mass, and the LVEDVi was 98.2 mL/m². This patient had an uncomplicated clinical course.

Infarct Definition and Size

The presence of acute infarction was established based on abnormalities in cine wall motion, rest first-pass myocardial perfusion, and delayed-enhancement imaging in 2 imaging planes. The myocardial mass of late gadolinium (grams) was quantified using computer-assisted planimetry and the territory of infarction was delineated using a signal intensity threshold of >5 SDs above a remote reference region and expressed as a percentage of total left ventricular mass.³⁹

Microvascular Obstruction

Microvascular obstruction was defined as a dark zone on early gadolinium enhancement imaging 1, 3, 5, and 7-minute postcontrast injection that remained present within an area of late gadolinium enhancement at 15 minutes.

Myocardial Edema

The extent of myocardial edema was defined as left ventricular myocardium with pixel values (T2) >2 SDs from remote myocardium.^{40–42}

Myocardial Salvage

Myocardial salvage was calculated by subtraction of percent infarct size from percent area-at-risk, as reflected by the extent of edema.^{40–42} The myocardial salvage index was calculated by dividing the myocardial salvage area by the initial area-at-risk.

Left Ventricular Remodeling

An increase in left ventricular volume at 6 months from baseline was taken to reflect left ventricular remodeling.³⁵

Myocardial Hemorrhage

On the T2* CMR maps, a region of reduced signal intensity within the infarcted area, with a T2* value of <20 ms^{22,43} was considered to confirm the presence of myocardial hemorrhage.

Prespecified Health Outcomes

We prespecified adverse health outcomes that are pathophysiologically linked with STEMI.^{44,45} The primary composite outcome was (1) all-cause death or first heart failure event after the initial hospitalization (Methods in the [online-only Data Supplement](#)).

Statistical Analyses

The sample size calculation and statistical methods are described in the [online-only Data Supplement](#). All *P* values are 2-sided and a *P* value >0.05 indicates the absence of a statistically significant effect. Statistical analyses were performed using R version 2.15.1 or SAS v 9.3 or higher versions of these programs.

Results

Patient Characteristics

Of 372 patients with acute STEMI who were screened, 324 (mean age, 59 [12] years; 237 [73%] male, 105 [32%] with hypertension) were enrolled (Table 1; Figure 2). The reasons for not being enrolled in the study are detailed in Figure 2. None of the participants had a new diagnosis of hypertension during the index admission.

Table 1. Clinical and Angiographic Characteristics of 324 STEMI Patients Categorized According to a History of Hypertension

Characteristics*	All Patients	No History of Hypertension		History of Hypertension		P Value
		Normal BP	High BP	Normal BP	High BP	
	n=324	n=154	n=63	n=67	n=38	
Age, y	59 (12)	58 (11)	55 (10)	66 (11)	60 (12)	<0.001 (A)
Male sex, n (%)	237 (73)	110 (71)	52 (83)	45 (67)	28 (74)	0.226
BMI, kg/m ²	29 (5)	28 (5)	29 (5)	29 (5)	30 (4)	0.069 (A)
Medical history						
Current smoking, n (%)	196 (61)	101 (66)	42 (67)	30 (45)	22 (58)	0.023
Hypercholesterolemia, n (%)	94 (29)	33 (21)	9 (14)	33 (49)	18 (47)	<0.001
Diabetes mellitus†, n (%)	34 (11)	15 (10)	3 (5)	12 (18)	4 (11)	0.113
Previous angina, n (%)	40 (12)	17 (11)	5 (8)	10 (15)	8 (21)	0.224
Previous myocardial infarction, n (%)	25 (8)	8 (5)	5 (8)	7 (10)	4 (11)	0.374
Previous PCI, n (%)	18 (6)	7 (5)	5 (8)	5 (8)	1 (3)	0.583
Presenting characteristics						
Heart rate, bpm	78 (17)	75 (16)	82 (19)	77 (15)	82 (17)	0.012 (A)
Systolic blood pressure, mm Hg	135 (25)	124 (17)	159 (16)	124 (20)	163 (18)	<0.001 (A)
Diastolic blood pressure, mm Hg	79 (14)	73 (10)	93 (9)	71 (11)	95 (9)	<0.001 (A)
Symptom onset to reperfusion time, min	174 (120–315)	171 (112–313)	208 (132–318)	209 (129–445)	144 (110–220)	0.028 (KW)
Ventricular fibrillation‡, n (%)	21 (7)	10 (7)	1 (2)	9 (13)	1 (3)	0.045
Killip class at presentation, n (%)						0.127
I	233 (72)	116 (75)	42 (67)	43 (64)	31 (82)	
II	68 (21)	31 (20)	16 (25)	14 (21)	6 (16)	
III/IV	23 (7)	7 (5)	5 (8)	10 (15)	1 (3)	
ST-segment resolution, n (%)						0.166
Complete ≥70%	148 (46)	81 (53)	25 (40)	30 (46)	11 (29)	
Incomplete 30% to <70%	127 (39)	54 (35)	28 (44)	26 (39)	18 (47)	
None ≤30%	48 (15)	19 (12)	10 (16)	10 (15)	9 (24)	
Reperfusion strategy, n (%)						0.804
Primary PCI	302 (93)	144 (94)	60 (95)	61 (91)	35 (92)	
Rescue PCI (failed thrombolysis)	14 (4)	5 (3)	2 (3)	5 (8)	2 (5)	
Successful thrombolysis	8 (3)	5 (3)	1 (2)	1 (2)	1 (3)	
Coronary angiography						
No. of diseased arteries§, n (%)						0.037
1	174 (54)	94 (61)	28 (44)	37 (55)	13 (34)	
2	99 (31)	43 (28)	23 (37)	17 (25)	16 (42)	
3	45 (14)	14 (9)	12 (19)	11 (16)	8 (21)	
Culprit coronary artery, n (%)						0.208
LM	6 (2)	3 (2)	0	2 (3)	1 (3)	
LAD	121 (37)	61 (40)	27 (43)	24 (36)	9 (24)	
LCX	59 (18)	25 (16)	14 (22)	8 (12)	10 (26)	
RCA	144 (44)	68 (44)	22 (35)	35 (52)	19 (50)	
TIMI coronary flow grade pre-PCI, n (%)						0.398
0/1	236 (73)	108 (70)	49 (78)	47 (70)	31 (82)	
2/3	88 (27)	46 (30)	14 (22)	20 (30)	7 (18)	

(Continued)

Table 1. Continued

Characteristics*	All Patients	No History of Hypertension		History of Hypertension		P Value
		Normal BP	High BP	Normal BP	High BP	
	n=324	n=154	n=63	n=67	n=38	
TIMI coronary flow grade post-PCI, n (%)						0.052
0/1	4 (1)	0	2 (3)	2 (3)	0	
2/3	320 (99)	154 (100)	61 (97)	65 (97)	38 (100)	
Microvascular function (angiography)						
TIMI frame count pre-PCI	30 (18–47)	28 (18–43)	24 (16–28)	38 (28–58)	34 (19–42)	0.068 (KW)
TIMI frame count post-PCI	16 (10–25)	14 (10–23)	17 (12–30)	18 (10–24)	19 (10–26)	0.266 (KW)
TIMI blush grade post-PCI, n (%)						0.505
0	70 (23)	33 (23)	15 (25)	13 (20)	9 (24)	
1	17 (6)	5 (3)	4 (7)	7 (11)	1 (3)	
2	157 (51)	71 (49)	28 (48)	35 (54)	21 (57)	
3	65 (21)	37 (25)	12 (20)	10 (15)	6 (16)	
Microvascular function (intracoronary sensor)						
Index of microvascular resistance	24 (15–44)	26 (15–43)	23 (15–37)	24 (15–50)	25 (17–49)	0.929 (KW)
Coronary flow reserve	1.6 (1.1–2.1)	1.5 (1.1–2.0)	1.8 (1.2–2.3)	1.6 (1.1–2.1)	1.4 (1.1–1.8)	0.170 (KW)
Resistance reserve ratio	1.8 (1.4–2.5)	1.8 (1.3–2.5)	2.3 (1.7–3.0)	1.8 (1.3–2.3)	1.8 (1.5–2.3)	0.261 (KW)
Treatment in the catheter laboratory, n (%)						
Aspiration thrombectomy	236 (73)	107 (70)	52 (83)	49 (73)	27 (71)	0.254
Glycoprotein IIb/IIIa inhibitor	297 (92)	144 (94)	56 (89)	59 (88)	36 (95)	0.402
Medical therapy						
ACE-I or ARB	320 (99)	151 (98)	62 (98)	67 (100)	38 (100)	0.796
β-Blocker	308 (95)	142 (92)	61 (97)	67 (100)	36 (95)	0.058
Statin	324 (100)	154 (100)	63 (100)	67 (100)	38 (100)	1.000
Antiplatelet therapy at discharge						
Aspirin	323 (100)	153 (99)	63 (100)	67 (100)	38 (100)	1.000
Clopidogrel	321 (99)	152 (99)	62 (98)	67 (100)	38 (100)	0.796
Blood results on admission						
Creatinine, μg/L	76 (65–89)	74 (65–87)	75 (64–87)	77 (70–91)	79 (65–98)	0.276 (KW)
C-reactive protein, mg/L	4 (2–7)	3 (2–6)	4 (2–8)	3 (2–9)	4 (2–7)	0.233 (KW)
Interleukin-6, pg/mL	7 (4–11)	7 (4–10)	6 (5–11)	8 (4–21)	9 (6–15)	0.503 (KW)
NT-proBNP	864 (345–1637)	651 (322–1437)	1208 (352–1637)	1208 (576–1924)	702 (299–1175)	0.310 (KW)
Troponin T, ng/L	1710 (110–5099)	1628 (256–4375)	1504 (106–5580)	1931 (101–5244)	1981 (210–5108)	0.976 (KW)

Killip classification of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary rales or crepitations, a third heart sound, and elevated jugular venous pressure; class III, acute pulmonary edema; class IV, cardiogenic shock. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LM, left main coronary artery; NT-proBNP, N-terminal Pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment-elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.

*Data are reported as mean (SD), median (interquartile range), or N (%) as appropriate. P values have been obtained from 1-way ANOVA (A), Kruskal-Wallis test (KW), or Fisher test. TIMI flow grades pre- and post-PCI were grouped 0/1 vs 2/3 for this analysis.

†Diabetes mellitus was defined as a history of diet-controlled or treated diabetes mellitus.

‡Successfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI procedure.

§Multivessel coronary artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter, by visual assessment and whether or not there was left main stem involvement. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) in the table represent measurements obtained at the start of emergency PCI. High blood pressure is defined as having SBP >140 mm Hg and DBP >80 mm Hg during the index admission.




Figure 2. Study flow diagram of the cohort study. CMR indicates cardiovascular magnetic resonance; and STEMI, ST-segment-elevation myocardial infarction.

Compared with patients without a history of hypertension, patients with a history of hypertension were older, had a history of hypercholesterolemia more often, but a history of cigarette smoking less often, and were more likely to have ventricular fibrillation at presentation and multivessel coronary artery disease (Table 1).

Microvascular Injury in the Culprit Coronary Artery and Inflammation

Angiographic parameters of blood flow and perfusion in the culprit coronary artery, IMR, and ST-segment resolution on the ECG (none versus partial versus complete) were similar between the groups (Table 1).

On day 1, circulating CRP, IL-6, and neutrophils and monocyte levels were also similar between the groups (Table 1).

CMR Imaging Findings

Three hundred twenty-four patients underwent CMR imaging 2.0 (1.8) days later, and 300 (93%) patients had follow-up CMR at 6 months (Table 2; Figure 2). Case examples are shown in Figure 1.

Infarct size was similar in patients with or without a history of hypertension (Table 2). However, left ventricular mass

index at baseline was associated with a history of hypertension in men (Table 2) and in both men and women with hypertension at 6-month post-STEMI (Table 2).

Left ventricular ejection fraction improved in all patients, however, compared with patients without a history of hypertension, the increase in ejection fraction was less in patients with a history of hypertension (Table 2).

Sex Differences and History of Hypertension

Left ventricular mass reduced to a lesser extent by 6 months in women with hypertension compared with in women without hypertension (Table 2).

BP at Initial Presentation

We observed associations between BP at the start of emergency PCI (normal BP [systolic BP ≤ 140 mmHg; diastolic BP ≤ 80 mmHg]; high BP [systolic BP > 140 mmHg; diastolic BP > 80 mmHg]) and clinical characteristics notably body mass index [normal BP versus high BP: 28.4 (4.8) versus 29.6 (4.7) kg/m²; $P=0.042$] but not vascular risk factors [smoking $P=0.54$]; hypercholesterolemia [$P=0.59$]) and microvascular dysfunction at the end of PCI as revealed by ST-segment

Table 2. Cardiac MRI Findings at 2 Days and 6 Months Postreperfusion in 324 STEMI Patients Categorized According to History of Hypertension

Characteristics*	All Patients	No History of Hypertension		History of Hypertension		P Value
		Normal BP	High BP	Normal BP	High BP	
	n=321	n=153	n=63	n=65	n=38	
CMR findings 2-d post-MI						
LV ejection fraction, %	55 (10)	55 (10)	53 (9)	56 (10)	56 (9)	0.178 (A)
LV end-diastolic volume index, mL/m ²						
Men	82 (15)	82 (14)	83 (15)	82 (17)	83 (15)	0.958 (A)
Women	72 (12)	73 (12)	73 (16)	73 (10)	70 (13)	0.901 (A)
LV end-systolic volume index, mL/m ²						
Men	38 (13)	39 (14)	40 (13)	37 (14)	38 (11)	0.804 (A)
Women	32 (10)	32 (10)	35 (10)	32 (9)	29 (9)	0.516 (A)
LV mass index, g/m ²						
Men	73 (15)	70 (14)	76 (13)	76 (17)	77 (16)	0.019 (A)
Women	58 (10)	55 (8)	64 (15)	58 (9)	61 (14)	0.065 (A)
Infarct characteristics						
Infarct size, %LV mass	16 (7 to 27)	15 (5 to 25)	19 (8 to 33)	20 (7 to 29)	15 (7 to 22)	0.102 (KW)
Myocardial salvage index, % of LV mass	63 (24)	66 (26)	58 (25)	61 (22)	63 (19)	0.174 (A)
Late microvascular obstruction, n (%)	164 (51)	75 (49)	33 (52)	36 (54)	19 (50)	0.902 (A)
Late microvascular obstruction, %LV mass	0 (0 to 4)	0 (0 to 3)	1 (0 to 4)	1 (0 to 6)	0 (0 to 3)	0.342 (KW)
Myocardial hemorrhage, n (%)	101 (41)	44 (38)	20 (39)	25 (49)	12 (46)	0.514 (A)
CMR findings 6-mo post-MI (n=267)						
LV ejection fraction at 6 mo, %	63 (57 to 69)	64 (59 to 70)	60 (55 to 66)	62 (54 to 69)	65 (59 to 71)	0.049 (KW)
Change in LV ejection fraction at 6 mo, %	7 (8)	8 (8)	7 (7)	4 (7)	7 (10)	0.037 (A)
LV mass index, g/m ²						
Men	63 (56 to 71)	61 (54 to 69)	63 (57 to 71)	67 (59 to 77)	68 (62 to 74)	0.004 (KW)
Women	53 (9)	49 (6)	54 (6)	57 (10)	60 (9)	<0.001 (A)
Change in LV mass index at 6 mo, g/m ²						
Men	−8 (13)	−7 (14)	−10 (13)	−7 (12)	−7 (9)	0.641 (A)
Women	−5 (8)	−7 (7)	−6 (8)	0 (11)	−4 (5)	0.022 (A)
LV end-systolic volume index at 6 mo, mL/m ²						
Men	32 (23 to 41)	30 (22 to 37)	35 (28 to 41)	33 (22 to 43)	31 (22 to 36)	0.208 (KW)
Women	27 (10)	25 (10)	29 (10)	30 (10)	26 (10)	0.231 (A)
Change in LV end-systolic volume index at 6 mo, mL/m ²						
Men	−4 (13)	−5 (13)	−4 (10)	0 (15)	−6 (13)	0.179 (A)
Women	−5 (8)	−6 (7)	−7 (8)	−2 (9)	−4 (9)	0.182 (A)

BMI indicates body mass index; BP, blood pressure; CMR, cardiac magnetic resonance; LV, left ventricle; MI, myocardial infarction; MRI, magnetic resonance imaging; and STEMI, ST-segment-elevation myocardial infarction.

Area-at-risk was measured with T2-mapping. Data are given as n (%) or mean (SD). *P* values were obtained from a 1-way ANOVA (A), Kruskal-Wallis test (KW), or a Fisher test. Native T1 (ms) was not associated with hypertension status (antecedent hypertension, yes vs no: remote zone, *P*=0.266; infarct zone, *P*=0.508; infarct core, *P*=0.205). High blood pressure is defined as having systolic BP (SBP) > 140 mm Hg and diastolic BP (DBP) > 80 mm Hg during the index admission.

*Data are reported as mean (SD), median (interquartile range), or n (%) as appropriate. LV ejection fraction was missing in 24 subjects at follow-up. LV end-diastolic volume index at follow-up was missing in 16 men and 8 women.

resolution (complete, none, partial: [normal BP versus high BP] 111 [50.5%], 29 [13.2%], 80 [36.4%] versus 36 [35.6%], 19 [18.8%], 46 [45.5%]; $P=0.041$).

Multivariable Associations Between Hypertension and Coronary Microvascular Pathology

Myocardial Hemorrhage

In a binary logistic regression model with baseline characteristics, a history of hypertension was a multivariable associate of myocardial hemorrhage (odds ratio, 1.81; [95% confidence interval, 0.98–53.34]; $P=0.059$; Table 3), albeit with wide confidence intervals.

Microvascular Dysfunction and Health Outcomes in the Longer Term

All ($n=324$) of the patients had long-term follow-up data completed. The median duration of follow-up was 1500 days (postdischarge censor duration [range] 1236 to 1801 days). Forty-seven (15%) patients died or experienced a first heart failure event during the index hospitalization or postdischarge. These events included 4 cardiovascular deaths, 11 noncardiovascular deaths, 2 deaths of undetermined cause, and 30 episodes of heart failure (Killip class 3 or 4 heart failure [$n=28$] or defibrillator implantation $n=2$). Twenty-three (7%) patients died or experienced a first heart failure hospitalization postdischarge.

A history of hypertension (odds ratio, 2.53; [95% confidence interval, 1.28–4.98]; $P=0.007$) was a multivariable associate of all-cause death or heart failure (Table 4).

Discussion

We have undertaken a large prospective imaging cohort study of hypertension status, microvascular pathophysiology, and long-term prognosis in patients with an acute STEMI. Uniquely, our study enrolled a high proportion of screened patients (nearly 9 of every 10 assessed), followed by serial multimodality assessments including use of invasive and noninvasive tests of reperfusion

Table 3. Multivariable Binary Logistic Regression Model of the Associations Between Clinical Characteristics, Including a History of Hypertension (Present or Absent), and the Occurrence of Myocardial Hemorrhage (Yes or No) 2 Days Later ($n=324$) in Patients With Acute STEMI

Binary Logistic Regression	Odds Ratio (95% Confidence Interval)	P Value
TIMI coronary flow grade 2/3 pre-PCI, n (%)	0.25 (0.12–0.51)	<0.001
ST-segment elevation resolution post-PCI, n (%)		
Incomplete 30% to <70%	2.44 (1.31–4.53)	0.005
None $\leq 30\%$	3.90 (1.69–9.02)	0.001
Cigarette smoker	2.55 (1.39–4.70)	0.003
Male sex	2.67 (1.33–5.38)	0.006
Hypertension	1.81 (0.98–3.34)	0.059
Harrel's C statistic: 0.746		

Manual backwards selection was used with a P value threshold of 0.10 for inclusion. Previous PCI was excluded because of numeric instability. The C statistic reflects the whole model. The univariable association between hypertension and myocardial hemorrhage was 1.5 (0.87–2.59); 0.143. PCI indicates percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.

Table 4. Multivariable Binary Logistic Regression Model for the Composite End Point (Yes or No) of All-Cause Death or First Hospitalization for Heart Failure, Including Clinical Characteristics (Present or Absent) at Baseline

Binary Logistic Regression	Odds Ratio (95% Confidence Interval)	P Value
History of myocardial infarction	6.19 (2.40–15.95)	<0.001
ST-segment elevation resolution post-PCI, n (%)		
Incomplete 30% to <70%	3.41 (1.54–7.56)	0.005
None $\leq 30\%$	4.13 (1.55–11.06)	0.001
Cigarette smoker	2.55 (1.39–4.70)	0.003
Hypertension	2.53 (1.28–4.98)	0.007
Harrel's C statistic: 0.746		

The median duration of follow-up was 4 y (1500 d [postdischarge censor duration (range) 1236–1801 d]). Forty-seven (15%) patients died or experienced a first heart failure event during the index hospitalization or postdischarge. Manual backwards selection was used with a P value threshold of 0.10 for inclusion. The C statistic reflects the whole model. The univariable association between hypertension and all-cause death or first hospitalization for heart failure was 2.52 (1.35–4.73); $P=0.004$. PCI indicates percutaneous coronary intervention.

injury, circulating measures of inflammation, serial imaging of infarct pathology and remodeling, and follow-up for health outcomes over a median of 4 years in all of the study participants.

The main findings are that antecedent hypertension was associated with (1) older age and less cigarette smoking; (2) a 2-fold increased likelihood of myocardial hemorrhage, albeit with wide confidence intervals, and less improvement in left ventricular systolic function at 6 months; (3) sex differences, specifically, for the associations between hypertension status and left ventricular outcomes in women but not in men; and (4) >2-fold increased risk of all-cause death or heart failure during a median of 4 years follow-up. Antecedent hypertension was not associated with infarct size, reperfusion injury, or systemic inflammation. BP status at initial presentation was associated with age, body mass index, and reperfusion injury as revealed by ST-segment resolution at the end of the PCI procedure.

Hypertension and Prognosis After Acute STEMI

In line with prior studies,^{11,12} we found that a history of hypertension is associated with risk factors for cardiovascular disease including age, smoking (less common),⁴⁶ and hypercholesterolemia (more common).

We also found that a history of hypertension was independently associated with an increased risk of all-cause death or hospitalization for heart failure. This result extends the evidence from previous studies. Notably, Reinstadler et al¹¹ found that antecedent hypertension was associated with a >3-fold risk of major adverse cardiac events at 12 months in a clinical trial population of 792 patients with acute STEMI.

Antecedent Hypertension, Sex, and Remodeling

Recent studies have reported conflicting information on the associations between antecedent hypertension and sex.^{11,12} Changes in left ventricular ejection fraction and remodeling at 6 months, including left ventricular end-systolic volume and mass, were less favorable in women with hypertension compared with women without hypertension. The enhanced

left ventricular mass in women with hypertension post-MI predisposes these individuals to adverse remodeling post-MI, and potentially, a worse cardiac prognosis in the longer term. Since the mean age of the participants was 59 years, an accelerated cardiovascular risk in postmenopausal women may be one contributing factor. Although reductions in mortality attributable to coronary heart disease have been observed in recent decades, no such decline has been observed in younger (<55 years) women.⁴⁷ Further research seems warranted.

Antecedent Hypertension, Microvascular Function, and Myocardial Hemorrhage Post-MI

We studied the relationships between microvascular resistance measured directly in the culprit coronary artery at the time of the acute STEMI and antecedent hypertension. Surprisingly, hypertension was not associated with acute reperfusion injury, as revealed by direct intracoronary measurements of microvascular resistance and by angiographic parameters (TIMI frame count, TIMI blush grade) or ST-segment resolution. The potential explanations for this finding include the prior use of antihypertensive therapies, such as angiotensin-converting enzyme inhibitors, which have protective effects on vascular function,²³ and the similar levels of arterial BP at the time of hospital admission in patients with a history of hypertension compared with BP levels in patients with no history of hypertension. This finding is in-keeping with the beneficial effects of both lifestyle and pharmacological measures to control BP. Because all of these parameters of coronary microvascular function are associated with prognosis post-MI,^{26,27,32} our findings rule out enhanced microvascular injury within the infarct zone as an explanation for the adverse prognosis in patients with antecedent hypertension.

Myocardial hemorrhage occurs in about one-third of patients with acute STEMI.^{21,22} This pathology reflects the end-stage consequence of irreversible microvascular dysfunction and is independently associated with adverse cardiac outcomes.^{21,22} In a time-course study,⁴⁸ we have previously shown that myocardial hemorrhage occurs in 2 phases after coronary reperfusion. The first phase occurs acutely within 12 hours. The second phase involves new, secondary bleeds that occur between days 1 and 3 in previously unaffected patients.⁴⁸ In this study, all patients who had evidence of new myocardial hemorrhage on day 3 had prior evidence of microvascular obstruction at 12 hours. We think that the temporal relationships between microvascular obstruction and myocardial hemorrhage may be relevant when considering their associations with hypertension status.

Microvascular function measured acutely and microvascular obstruction revealed by CMR 2 days later were not associated with hypertension status. However, myocardial hemorrhage, as specifically revealed by T2* mapping (Figure 1) was associated with a near 2-fold increased risk of hypertension, independent of other predictors. The result was not statistically significant and thus hypothesis generating. Cigarette smoking status is a multivariable, positive associate of myocardial hemorrhage after an acute STEMI (Table 3)⁴⁸ and the inverse association between hypertension and smoking status may be a relevant confounding factor.

We undertook a time-course study with repeated assessments to assess the temporal evolution of microvascular injury

acutely and then subsequently 2 to 3 days later using CMR. Long-term follow-up of this cohort permitted an analysis of the prognostic significance of microvascular injury early post-MI. Myocardial hemorrhage reflects vascular degradation and capillary leak of red blood cells. Hemorrhage within the infarct zone as revealed by CMR (Figure 1) is a direct measure of end-stage vascular injury post-MI. Our findings lead to a conclusion that despite a similar extent of acute microvascular injury and infarct size, vascular degradation at 2 days is greater in patients with a history of hypertension compared with in patients with no prior hypertension. We hypothesize that the microvessels of patients with hypertension are less capable of maintaining vascular integrity under conditions of ischemia/reperfusion injury.⁴⁹ Given that hemorrhage may develop progressively in a secondary phase (days 2–3), impaired vascular homeostasis and repair potential in patients with chronic hypertension may be explanations for these results. Such patients may have preexisting coronary microvascular disease,^{15,16} and the microvessels subtended by the culprit artery may be less resistant to the effects of reperfusion injury (acidosis, oxidants, etc), leading to progressive capillary degradation and infarct zone hemorrhage. A susceptibility to hemorrhagic transformation within the infarct zone may provide a new mechanistic explanation for why patients with antecedent hypertension have a worse prognosis despite infarct size being similar to patients without prior hypertension.^{11,12} Accumulation of deoxyhemoglobin and iron within the infarct zone may serve as a mechanistic substrate for enhanced scar formation and abnormal left ventricular remodeling.⁵⁰ Our results suggest that progressive microvascular damage within the infarct zone in patients with antecedent hypertension may underpin an impaired recovery potential within the heart, leading in turn to left ventricular systolic dysfunction and heart failure in the longer term.

We did not find any association between hypertension status and infarct size, as reflected by contrast-enhanced CMR and peak troponin concentration. This result is consistent with reports by Reinstadler et al¹¹ and De Luca et al.¹² We did not observe any association between hypertension status and circulating measures of inflammation. This result could potentially be explained by the anti-inflammatory effects of antihypertensive drug therapies, such as angiotensin-converting enzyme inhibitors.

Our results provide further evidence that a history of hypertension in patients with an acute STEMI is associated with a worse prognosis. In terms of clinical translation, our results highlight that patients with a history of hypertension are at an increased risk of developing heart failure. The results support further research into therapeutic strategies designed to preserve vascular integrity and repair potential within the vascular distribution of the culprit coronary artery.

Limitations

Our analysis does not permit inference on causality, and further studies are warranted. We lacked detailed information on BP history and compliance with antihypertensive drug therapy before the index hospitalization.

Perspectives

In summary, we have studied the complex relationships between hypertension status, concomitant risk factors,

infarct pathology, left ventricular remodeling, and health outcomes in a large cohort of STEMI patients. We found that a history of hypertension in patients with acute STEMI is independently associated less improvement in left ventricular systolic function, notably in women, and an increased risk of all-cause death and heart failure in the longer term. An increased propensity to myocardial hemorrhage may be one mechanistic explanation, reflecting severe microvascular injury.

Our results confirm and extend previous investigations and support further research into therapeutic strategies that attenuate reperfusion injury within the infarct zone in patients with acute STEMI.

Acknowledgments

We thank the patients who participated in this study and the staff in the Cardiology and Radiology Departments. We thank Peter Weale and Patrick Revell (Siemens Healthcare, United Kingdom).

Sources of Funding

This study was supported by the British Heart Foundation (BHF) Centre of Research Excellence Award (RE/13/5/30177), the BHF Project Grant PG/11/2/28474, the National Health Service, and the Chief Scientist Office. C. Berry was supported by a Senior Fellowship from the Scottish Funding Council. P. Welsh is supported by BHF Fellowship FS/12/62/29889. A.M. Maznyczka is supported by BHF Fellowship FS/16/74/32573.

Disclosures

Based on institutional agreements with the University of Glasgow, Siemens Healthcare has provided work-in-progress imaging methods and C. Berry has acted as a consultant to Abbott Vascular. K.G. Oldroyd has acted as consultant to Abbott Vascular and Volcano Corporation. These companies had no involvement in the current research or the article. The other authors report no conflicts.

References

- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903–1913. doi: 10.1016/S0140-6736(02)11911-8.
- Benjamin EJ, Blaha MJ, Chiuve SE, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation*. 2017;135:e146–e603. doi: 10.1161/CIR.0000000000000485.
- British Heart Foundation. Cardiovascular Disease Statistics Factsheet (UK). <https://www.bhf.org.uk/statistics>. Accessed April 27, 2018.
- Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. *Hypertension*. 2008;51:48–54. doi: 10.1161/HYPERTENSIONAHA.107.093682.
- Fresco C, Avanzini F, Bosi S, Franzosi MG, Maggioni AP, Santoro L, Bellanti G. Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with thrombolysis. GISSI-2 Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. *J Hypertens*. 1996;14:743–750.
- Richards AM, Nicholls MG, Troughton RW, Lainchbury JG, Elliott J, Frampton C, Espiner EA, Crozier IG, Yandle TG, Turner J. Antecedent hypertension and heart failure after myocardial infarction. *J Am Coll Cardiol*. 2002;39:1182–1188.
- Lee MG, Jeong MH, Lee KH, Park KH, Sim DS, Yoon HJ, Yoon NS, Kim KH, Park HW, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Prognostic impact of diabetes mellitus and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary intervention. *J Cardiol*. 2012;60:257–263. doi: 10.1016/j.jjcc.2012.06.003.
- De Luca G, van't Hof AW, Huber K, et al; EGYPT cooperation. Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty. *Am J Cardiol*. 2013;112:1083–1086. doi: 10.1016/j.amjcard.2013.05.053.
- De Luca G, Dirksen MT, Spaulding C, et al; DESERT cooperation. Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES: insights from the DESERT cooperation. *Int J Cardiol*. 2014;175:50–54. doi: 10.1016/j.ijcard.2014.04.180.
- Chen G, Hemmelgarn B, Alhaider S, Quan H, Campbell N, Rabi D. Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction. *Am J Cardiol*. 2009;104:141–147. doi: 10.1016/j.amjcard.2009.02.048.
- Reinstadler SJ, Stiermaier T, Eitel C, Saad M, Metzler B, de Waha S, Fuernau G, Desch S, Thiele H, Eitel I. Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction. *J Cardiovasc Magn Reson*. 2016;18:80. doi: 10.1186/s12968-016-0299-1.
- De Luca G, Parodi G, Sciagra R, Bellandi B, Comito V, Vergara R, Migliorini A, Valenti R, Antonucci D. Impact of hypertension on infarct size in ST elevation myocardial infarction patients undergoing primary angioplasty. *J Hypertens*. 2013;31:2433–2437. doi: 10.1097/HJH.0b013e328364cbee.
- Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. *Ann Intern Med*. 1961;55:33–50.
- Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. *Ann Intern Med*. 1970;72:813–822.
- Brush JE Jr, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. *J Am Coll Cardiol*. 1992;19:809–815.
- Lehmann N, Erbel R, Mahabadi AA, Kalsch H, Möhlenkamp S, Moebus S, Stang A, Roggenbuck U, Strucksberg KH, Führer-Sakel D, Dragano N, Budde T, Seibel R, Grönemeyer D, Jöckel KH; Heinz Nixdorf Recall Study Investigators. Accelerated progression of coronary artery calcification in hypertension but also prehypertension. *J Hypertens*. 2016;34:2233–2242. doi: 10.1097/HJH.0000000000001080.
- Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. *J Am Coll Cardiol*. 2006;48:833–838. doi: 10.1016/j.jacc.2006.05.045.
- Candemir B, Ertas FS, Ozdol C, Kaya CT, Kilickap M, Akyurek O, Atmaca Y, Kumbasar D, Erol C. Effect of hypertension on coronary remodeling patterns in angiographically normal or minimally atherosclerotic coronary arteries: an intravascular ultrasound study. *Clin Exp Hypertens*. 2012;34:432–438. doi: 10.3109/10641963.2012.665544.
- Hamasaki S, Al Suwaidi J, Higano ST, Miyauchi K, Holmes DR Jr, Lerman A. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. *J Am Coll Cardiol*. 2000;35:1654–1660.
- Homsi R, Sprinkart AM, Gieseke J, Yucel S, Meier-Schroers M, Luetkens J, Dabir D, Kuetting D, Marx C, Nadal J, Schild HH, Thomas D. 3D-Dixon cardiac magnetic resonance detects an increased epicardial fat volume in hypertensive men with myocardial infarction. *Eur J Radiol*. 2016;85:936–942. doi: 10.1016/j.ejrad.2016.02.016.
- Eitel I, Kubusch K, Strohm O, Desch S, Mikami Y, de Waha S, Gutberlet M, Schuler G, Friedrich MG, Thiele H. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. *Circ Cardiovasc Imaging*. 2011;4:354–362. doi: 10.1161/CIRCIMAGING.110.960500.
- Carrick D, Haig C, Ahmed N, et al. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. *Circ Cardiovasc Imaging*. 2016;9:e004148. doi: 10.1161/CIRCIMAGING.115.004148.
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013;34:2159–2219. doi: 10.1093/eurheartj/ehs151.
- Steg PG, James SK, Atar D, et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33:2569–619. doi: 10.1093/eurheartj/ehs215.

25. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. phase I findings. *N Engl J Med*. 1985;312:932–936. doi: 10.1056/NEJM19850403121437.
26. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. *Circulation*. 1996;93:879–888.
27. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. *Circulation*. 2000;101:125–130.
28. Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, Schnitger I, Lee DP, Vagelos RH, Fitzgerald PJ, Yock PG, Yeung AC. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2008;51:560–565. doi: 10.1016/j.jacc.2007.08.062.
29. McGeoch R, Watkins S, Berry C, Steedman T, Davie A, Byrne J, Hillis S, Lindsay M, Robb S, Dargie H, Oldroyd K. The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv*. 2010;3:715–722. doi: 10.1016/j.jcin.2010.04.009.
30. Payne AR, Berry C, Doolin O, McEntegart M, Petrie MC, Lindsay MM, Hood S, Carrick D, Tzemos N, Weale P, McComb C, Foster J, Ford I, Oldroyd KG. Microvascular resistance predicts myocardial salvage and infarct characteristics in ST-elevation myocardial infarction. *J Am Heart Assoc*. 2012;1:e002246. doi: 10.1161/JAHA.112.002246.
31. Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim HS, Loh JP, Oldroyd KG. Prognostic value of the index of microcirculatory resistance measured after primary percutaneous coronary intervention. *Circulation*. 2013;127:2436–2441. doi: 10.1161/CIRCULATIONAHA.112.000298.
32. Carrick D, Haig C, Ahmed N, et al. Comparative prognostic utility of indexes of microvascular function alone or in combination in patients with an acute ST-segment-elevation myocardial infarction. *Circulation*. 2016;134:1833–1847. doi: 10.1161/CIRCULATIONAHA.116.022603.
33. Sattar N, Murray HM, Welsh P, et al; Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? *PLoS Med*. 2009;6:e1000099. doi: 10.1371/journal.pmed.1000099.
34. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E; Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. *J Cardiovasc Magn Reson*. 2013;15:91. doi: 10.1186/1532-429X-15-91.
35. Carrick D, Haig C, Rauhalaammi S, et al. Pathophysiology of LV remodeling in survivors of STEMI: inflammation, remote myocardium, and prognosis. *JACC Cardiovasc Imaging*. 2015;8:779–789. doi: 10.1016/j.jcmg.2015.03.007.
36. Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP. T2 quantification for improved detection of myocardial edema. *J Cardiovasc Magn Reson*. 2009;11:56. doi: 10.1186/1532-429X-11-56.
37. Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP, Raman SV. Direct T2 quantification of myocardial edema in acute ischemic injury. *JACC Cardiovasc Imaging*. 2011;4:269–278. doi: 10.1016/j.jcmg.2010.09.023.
38. Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. *Magn Reson Med*. 2002;47:372–383.
39. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. *JACC Cardiovasc Imaging*. 2011;4:150–156. doi: 10.1016/j.jcmg.2010.11.015.
40. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. *J Am Coll Cardiol*. 2010;55:2470–2479. doi: 10.1016/j.jacc.2010.01.049.
41. Berry C, Kellman P, Mancini C, Chen MY, Bandettini WP, Lowrey T, Hsu LY, Aletras AH, Arai AE. Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. *Circ Cardiovasc Imaging*. 2010;3:527–535. doi: 10.1161/CIRCIMAGING.109.900761.
42. Payne AR, Casey M, McClure J, McGeoch R, Murphy A, Woodward R, Saul A, Bi X, Zuehlisdruff S, Oldroyd KG, Tzemos N, Berry C. Bright-blood T2-weighted MRI has higher diagnostic accuracy than dark-blood short tau inversion recovery MRI for detection of acute myocardial infarction and for assessment of the ischemic area at risk and myocardial salvage. *Circ Cardiovasc Imaging*. 2011;4:210–219. doi: 10.1161/CIRCIMAGING.110.960450.
43. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J*. 2001;22:2171–2179.
44. Thygesen K, Alpert JS, Jaffe AS, et al; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. *Circulation*. 2012;126:2020–2035. doi: 10.1161/CIR.0b013e31826e1058.
45. Hicks KA, Tcheng JE, Bozkurt B, et al; American College of Cardiology; American Heart Association. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). *Circulation*. 2015;132:302–361. doi: 10.1161/CIR.0000000000000156.
46. Reinstadler SJ, Eitel C, Fuernau G, de Waha S, Desch S, Mende M, Metzler B, Schuler G, Thiele H, Eitel I. Association of smoking with myocardial injury and clinical outcome in patients undergoing mechanical reperfusion for ST-elevation myocardial infarction. *Eur Heart J Cardiovasc Imaging*. 2017;18:39–45. doi: 10.1093/ehjci/jew030.
47. Wilms KA, O'Flaherty M, Capewell S, Ford ES, Vaccarino V. Coronary heart disease mortality declines in the United States from 1979 through 2011: evidence for stagnation in young adults, especially women. *Circulation*. 2015;132:997–1002. doi: 10.1161/CIRCULATIONAHA.115.015293.
48. Symons R, Masci PG, Francone M, Claus P, Barison A, Carbone I, Agati L, Galea N, Janssens S, Bogaert J. Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker's paradox revisited. *Eur Heart J*. 2016;37:2756–2764. doi: 10.1093/eurheartj/ehv738.
49. Carrick D, Haig C, Ahmed N, et al. Temporal evolution of myocardial hemorrhage and edema in patients after acute ST-segment elevation myocardial infarction: pathophysiological insights and clinical implications. *J Am Heart Assoc*. 2016;5:e002834. doi: 10.1161/JAHA.115.002834.
50. Bulluck H, Rosmini S, Abdel-Gadir A, et al. Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling. *Circ Cardiovasc Imaging*. 2016;9:e004940. doi: 10.1161/CIRCIMAGING.116.004940.

Novelty and Significance

What Is New?

- The pathological and prognostic significance of a history of hypertension was assessed in a reasonably large cohort of patients with acute ST-segment-elevation myocardial infarction treated by emergency percutaneous coronary intervention.
- Hypertension was associated with a near 2-fold increased likelihood of myocardial hemorrhage, reflecting severe microvascular injury.
- Hypertension was associated with less favorable changes in left ventricular ejection fraction and remodeling, notably in women, and hypertension was associated with a higher risk of all-cause death and heart failure.

What Is Relevant?

- A history of hypertension is associated with a worse prognosis.
- Patients with acute ST-segment-elevation myocardial infarction and a history of hypertension merit intensive medical management.

Summary

Our results confirm and extend previous investigations and support further research into therapeutic strategies that attenuate reperfusion injury within the infarct zone in patients with acute ST-segment-elevation myocardial infarction.